Latest Financials News

Wisr Limited reported a robust Q3FY25 with loan originations surging 115% year-on-year and a second consecutive quarter of loan book growth, prompting an upgrade to its FY25 loan origination guidance.

Artemis Resources has reported significant high-grade gold intersections from its initial diamond drilling phase near the Carlow deposit, while also consolidating lithium rights in a new joint venture with GreenTech Metals, positioning itself strongly in Western Australia’s mineral landscape.

Lark Distilling Co. reported a robust Q3FY25 with net sales rising 31% to $4.3 million, driven by growth in travel retail, ecommerce, and exclusive whisky releases. The company also progressed its Pontville distillery redevelopment and maintained positive operating cash flow.

Top End Energy has completed its strategic acquisition of Serpentine Energy, significantly expanding its natural hydrogen footprint in Kansas and advancing towards its first well drilling, while also progressing exploration in Australia’s Northern Territory.

Traka Resources has made a strategic leap into West Africa with a joint venture on the Didi Gold Project in Guinea, positioning itself near AngloGold Ashanti’s prolific Siguiri Mine. The company plans targeted drilling next quarter while maintaining its Australian exploration assets.

Island Pharmaceuticals has completed dosing in the Phase 2b cohort of its dengue fever trial, with pharmacokinetic targets met and top-line results expected next month. The company also strengthened its balance sheet by raising $1.94 million through option exercises.

Top End Energy Limited reported a mixed quarterly cash flow with operating and investing outflows offset by robust financing inflows, ending March 2025 with over five quarters of funding available.

PeopleIn Limited reported a $6.3 million Q3 FY25 EBITDA, down from $6.9 million last year, affected by severe weather in Queensland. Strong cash flow helped reduce debt, underscoring resilience despite ongoing trading challenges.

Santos Limited’s 2024 Annual Report reveals a 5% drop in production and a 9% decline in sales revenue, yet highlights significant progress in carbon capture and storage and emissions reduction targets.

Tryptamine Therapeutics has secured a landmark agreement with Swinburne University to initiate the first clinical trial of its IV-infused psilocin formulation TRP-8803 for Binge Eating Disorder, aiming to build on promising Phase 2a data.

Southern Palladium’s March quarter report highlights strong project economics from its Bengwenyama PGM project, with a $1.06 billion NPV and a mining right decision expected in Q2 2025. The company is progressing a Definitive Feasibility Study and project optimisation to accelerate production.

Amplia Therapeutics has completed recruitment early for its Phase 2a ACCENT trial in advanced pancreatic cancer, reporting encouraging interim results and advancing a second trial with FDA-backed protocol changes.